🔍

BALAXI - Balaxi Pharma

📊 NSE: BALAXI 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/13/2025 18:58

📢 Recent Corporate Announcements

Balaxi Pharma Reports Nil Physical Share Transfer Re-lodgement Requests for Feb-Mar 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 14 Apr 2026, 12:10 PM

Balaxi Pharmaceuticals has filed its RTA report for the months of February and March 2026 regarding the re-lodgement of physical share transfer requests. The report, submitted in compliance with a SEBI circular from January 2026, indicates that zero requests were received, processed, or rejected during this period. This is a standard regulatory disclosure and does not reflect any change in the company's operational or financial status. The filing confirms that the company's Registrar and Share Transfer Agent, Aarthi Consultants Private Limited, is monitoring the special window for physical share transfers as required.

Zero requests received for re-lodgement of physical share transfers in February 2026.
Zero requests received for re-lodgement of physical share transfers in March 2026.
Compliance maintained with SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026.
Report issued by Registrar and Share Transfer Agent, Aarthi Consultants Private Limited.
Average time taken for processing requests was reported as NIL due to lack of activity.

💡 No action is required from investors as this is a routine administrative filing with no impact on the company's valuation or business prospects.

Balaxi Pharmaceuticals Submits SEBI Compliance Certificate for Q4 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 09 Apr 2026, 05:19 PM

Balaxi Pharmaceuticals has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations for the period ending March 31, 2026. The certificate, issued by the Registrar and Share Transfer Agent, Aarthi Consultants Private Limited, confirms that all share certificates received for dematerialization were processed within the mandated 15-day timeframe. This process includes the mutilation and cancellation of physical certificates and the substitution of the depository's name in the company's records. This is a standard administrative filing required for all listed companies in India.

Compliance certificate submitted for the quarter ended March 31, 2026.
Registrar confirmed processing of dematerialization requests within the 15-day regulatory limit.
Physical security certificates were mutilated and cancelled as per SEBI guidelines.
The depository's name was updated as the registered owner in the company records for dematerialized shares.

💡 No action is required from investors as this is a routine regulatory filing confirming administrative compliance regarding share dematerialization.

Balaxi Pharmaceuticals Clarifies Recent Price Volatility; Cites Market-Driven Factors

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 09 Apr 2026, 11:12 AM

Balaxi Pharmaceuticals Limited has responded to a clarification request from the National Stock Exchange (NSE) regarding significant recent movements in its share price. The company officially stated that there is no undisclosed material information or pending announcements that could influence the stock's price or volume. Management maintains that the recent price behavior is purely market-driven and not based on internal developments. The company reaffirmed its commitment to complying with SEBI (LODR) Regulations, 2015, for all future disclosures.

NSE issued a surveillance letter (NSE/CM/Surveillance/16689) on April 8, 2026, seeking clarification on price movement.
Balaxi Pharmaceuticals submitted its formal response on April 9, 2026, denying any hidden material events.
The company confirmed that all disclosures under Regulation 30 of SEBI (LODR) are up to date.
Management attributed the recent fluctuations in equity share price and volume strictly to market forces.

💡 As the company has denied any undisclosed material developments, investors should exercise caution and avoid speculative trading based on recent price volatility. Focus on upcoming quarterly earnings or fundamental business updates for long-term decision making.

CRISIL Downgrades Balaxi Pharma to 'BBB/Stable' as Operating Margins Expected to Drop to 5%

🔴 NEGATIVE ⭐ 7/10

REGULATORY 📅 02 Apr 2026, 12:35 PM

CRISIL has downgraded Balaxi Pharmaceuticals' long-term rating from 'BBB+' to 'BBB', though it revised the outlook from 'Negative' to 'Stable'. The downgrade reflects significant pressure on profitability due to high marketing expenditures required for the company's shift toward institutional sales. Operating margins are expected to compress sharply to 5% in FY26 from 12% in FY25, while the working capital cycle remains stretched at 295 days. Despite these challenges, the company maintains a healthy capital structure with a gearing ratio of 0.25x and a net worth of Rs 204.9 crore.

Long-term bank facility rating downgraded to 'CRISIL BBB' from 'CRISIL BBB+'
Operating margins projected to decline to 5% in FY26 from 12% in the previous fiscal year
9M FY26 net profit fell sharply to Rs 0.80 crore compared to Rs 16.43 crore in 9M FY25
Working capital cycle remains intensive with Gross Current Assets (GCA) at 295 days as of March 2025
Revenue concentration risk persists with over 50% of total revenue sourced from Angola

💡 Investors should monitor the company's ability to stabilize margins during its transition to institutional sales and track the progress of its Indian manufacturing facility expected in FY27. The significant drop in net profit and stretched working capital suggest short-term liquidity and profitability headwinds.

Balaxi Pharmaceuticals to Close Trading Window from April 1, 2026 for Q4 and FY26 Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 27 Mar 2026, 01:00 AM

Balaxi Pharmaceuticals Limited has informed the stock exchange that its trading window will be closed starting April 1, 2026. This closure is a mandatory compliance step under SEBI (Prohibition of Insider Trading) Regulations, 2015. The restriction applies to all designated persons and their immediate relatives ahead of the announcement of audited financial results for the fourth quarter and full financial year ending March 31, 2026. The window will reopen 48 hours after the results are officially declared.

Trading window closure effective from April 1, 2026, for all designated persons.
Closure is in anticipation of the Audited Financial Results for Q4 and FY ending March 31, 2026.
The window will remain closed until 48 hours after the board meeting results are announced.
The specific date for the board meeting to consider results will be informed in due course.

💡 No action is required as this is a routine regulatory filing. Investors should wait for the announcement of the board meeting date to assess the company's annual financial performance.

Balaxi Pharma Designates KMPs for Materiality Determination under SEBI Regulations

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 25 Mar 2026, 01:18 PM

Balaxi Pharmaceuticals has updated its list of Key Managerial Personnel (KMP) authorized to determine the materiality of events for stock exchange disclosures. This action is in compliance with Regulation 30(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The authorized personnel include Mr. Ashish Maheshwari, Chairman and Managing Director, and Mr. Aman Purohit, Company Secretary and Compliance Officer. This is a procedural update to ensure transparent and timely reporting of significant company developments to investors.

Authorized Mr. Ashish Maheshwari (Chairman and MD) to determine event materiality.
Authorized Mr. Aman Purohit (Company Secretary) for disclosure and materiality assessment.
Compliance with Regulation 30(5) of SEBI (LODR) Regulations, 2015.
Contact details provided for the designated KMPs at the Hyderabad corporate office.

💡 No immediate action is required as this is a routine administrative disclosure. Investors should note the contact details for future materiality-related queries.

Balaxi Pharmaceuticals Appoints Aman Purohit as Company Secretary and Compliance Officer

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 25 Mar 2026, 01:14 PM

Balaxi Pharmaceuticals Limited has appointed Mr. Aman Purohit as the Company Secretary and Compliance Officer, effective March 25, 2026. Mr. Purohit is an Associate Member of the ICSI with over 6 years of post-qualification experience in secretarial compliance and corporate restructuring. He has previously worked with firms like Patil Rail Infrastructure and Re Sustainability IWM Solutions. This appointment is a routine regulatory requirement to ensure the company's adherence to statutory norms.

Appointment of Mr. Aman Purohit as Company Secretary and Compliance Officer effective March 25, 2026
Mr. Purohit brings 6 years of experience in secretarial compliance, M&A, and fund raising
He holds ICSI Membership Number A59345 and a B.Com (Hons) from the University of Calcutta
The Board meeting for the approval commenced at 11:45 a.m. and concluded at 12:50 p.m.

💡 No immediate action is required as this is a routine administrative appointment to maintain regulatory compliance. Investors should view this as a standard management update.

Balaxi Pharmaceuticals Appoints Aman Purohit as Company Secretary and Compliance Officer

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 25 Mar 2026, 01:12 PM

Balaxi Pharmaceuticals Limited has appointed Mr. Aman Purohit as the Company Secretary and Compliance Officer effective March 25, 2026. Mr. Purohit is an Associate Member of the ICSI with over 6 years of post-qualification experience in secretarial compliance and corporate restructuring. His background includes handling mergers, acquisitions, and fund-raising activities in previous roles. This appointment is a routine regulatory requirement to ensure the company maintains its compliance standards.

Appointment of Mr. Aman Purohit as Company Secretary and Compliance Officer effective March 25, 2026
Mr. Purohit brings 6 years of specialized experience in secretarial compliance and corporate restructuring
He is an Associate Member of the Institute of Company Secretaries of India (ICSI Membership No: A59345)
The Board meeting approving the appointment concluded within approximately 65 minutes on March 25, 2026

💡 This is a routine administrative appointment and should not impact the stock's valuation. No immediate action is required from investors.

Balaxi Pharmaceuticals Appoints Aman Purohit as Company Secretary and Compliance Officer

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 25 Mar 2026, 01:10 PM

Balaxi Pharmaceuticals Limited has announced the appointment of Mr. Aman Purohit as the Company Secretary and Compliance Officer, effective March 25, 2026. The decision was finalized during a Board meeting held on the same day between 11:45 a.m. and 12:50 p.m. Mr. Purohit is an Associate Member of ICSI with 6 years of post-qualification experience in secretarial compliance and corporate restructuring. This appointment ensures the company remains compliant with SEBI regulations and listing requirements.

Appointment of Mr. Aman Purohit as CS and Compliance Officer effective March 25, 2026
Mr. Purohit brings 6 years of experience in secretarial compliance, M&A, and corporate restructuring
He is an Associate Member of ICSI (Membership No: A59345) and a B.Com (Hons) graduate
The Board meeting for the approval lasted 65 minutes on March 25, 2026

💡 This is a routine administrative appointment to fill a mandatory regulatory position. No immediate action is required from investors.

Balaxi Pharma Appoints Aman Purohit as CS & Compliance Officer Effective March 25, 2026

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 25 Mar 2026, 01:07 PM

Balaxi Pharmaceuticals has appointed Mr. Aman Purohit as the Company Secretary and Compliance Officer, effective March 25, 2026. Mr. Purohit is a qualified professional with over 6 years of experience in secretarial compliance, corporate restructuring, and fund raising. This appointment was approved by the Board of Directors following the recommendation of the Nomination and Remuneration Committee. The transition ensures the company remains compliant with SEBI regulations and statutory requirements.

Appointment of Mr. Aman Purohit as Company Secretary and Compliance Officer effective March 25, 2026
Mr. Purohit brings 6 years of post-qualification experience in secretarial compliance and M&A
He is an Associate Member of ICSI (A59345) and a B.Com (Hons) from the University of Calcutta
The appointment follows the recommendation of the Nomination and Remuneration Committee

💡 No immediate action is required as this is a routine administrative appointment. Investors should focus on the company's upcoming financial results and growth strategy.

Balaxi Pharma Q3 FY26: Revenue at ₹72.54 Cr, PAT Declines to ₹0.31 Cr Amid Strategic Shift

🔵 WATCH ⭐ 7/10

EARNINGS 📅 29 Jan 2026, 02:45 PM

Balaxi Pharmaceuticals reported a marginal 1% YoY decline in Q3 FY26 revenue to ₹72.54 crore, though it saw a strong 29% sequential recovery from Q2. Profit After Tax (PAT) dropped significantly to ₹0.31 crore from ₹5.36 crore last year, primarily due to higher operating costs and challenges in the Angola market's institutional segment. The company successfully completed the qualification and validation of its first pharmaceutical formulation facility in Hyderabad, marking a shift to an 'Asset Right' model. Despite near-term margin pressure, the LATAM region remains a strong growth driver with 13 new product registrations added this quarter.

Revenue for Q3 FY26 stood at ₹72.54 crore, showing a 29% QoQ growth despite a 1% YoY dip.
PAT plummeted to ₹0.31 crore from ₹5.36 crore YoY due to elevated operating costs in institutional segments.
Total product registrations reached 948 across geographies, with 13 new registrations added in Q3.
The new Jadcherla formulation facility is now audit-ready, completing qualification and validation of equipment.
Gross margins moderated to 42% compared to 48% in the previous year's corresponding quarter.

💡 Investors should monitor the margin recovery as the new manufacturing facility begins to contribute to backward integration. The transition from 'Asset Light' to 'Asset Right' is a major strategic shift that may weigh on short-term profits but improve long-term supply chain control.

Balaxi Pharma Reports Zero Deviation in Utilization of ₹47.57 Crore Raised Funds

🟢 POSITIVE ⭐ 6/10

REGULATORY 📅 28 Jan 2026, 03:39 PM

Balaxi Pharmaceuticals has submitted its statement of deviation for the quarter ended December 31, 2025, confirming that funds raised through its preferential issue are being used as intended. Out of the total ₹47.57 crore raised via equity shares and convertible warrants, the company has utilized approximately ₹34.22 crore to date. The proceeds are primarily being deployed for the construction of a new pharmaceutical formulation plant in Jadcherla, Hyderabad, and for working capital requirements. The report indicates zero deviation from the objects stated during the fundraise, reflecting disciplined financial management.

Total amount raised through preferential issue and warrant conversions is ₹47,56,92,250.
Cumulative funds utilized as of December 31, 2025, amount to ₹34,21,66,871.
The company reported zero deviation or variation in the use of proceeds for the reported quarter.
Funds are being utilized for capital expenditure on a new formulation plant in Jadcherla and general corporate purposes.

💡 Investors should view the lack of deviation as a positive sign of management integrity and focus on the upcoming Jadcherla plant as a key growth catalyst. Monitor the completion timeline of the facility to gauge future production capacity increases.

Balaxi Pharma Q3 Consolidated Net Profit Drops 94% YoY to ₹30.5 Lakhs; Jadcherla Plant Ready

🔴 NEGATIVE ⭐ 8/10

EARNINGS 📅 28 Jan 2026, 02:55 PM

Balaxi Pharmaceuticals reported a significant decline in consolidated net profit to ₹30.50 lakhs for Q3 FY26, compared to ₹536.28 lakhs in the same period last year. While consolidated revenue remained relatively stable at ₹72.54 crore, higher administrative and employee expenses impacted the bottom line. On a positive note, the company's first pharmaceutical formulation plant at Jadcherla is now fully ready for CDSCO inspection following successful test manufacturing. Additionally, the Company Secretary and Compliance Officer has resigned effective January 29, 2026.

Consolidated Net Profit fell sharply to ₹30.50 lakhs in Q3 FY26 from ₹536.28 lakhs in Q3 FY25.
Consolidated Revenue from operations stood at ₹72.54 crore, a marginal decline from ₹73.29 crore YoY.
Jadcherla formulation facility is audit-ready for CDSCO inspection with successful test batches of Paracetamol and Piroxicam.
Consolidated EPS for the quarter dropped to ₹0.06 from ₹0.97 in the previous year's corresponding quarter.
Company Secretary Mohith Kumar Khandelwal resigned effective January 29, 2026.

💡 Investors should exercise caution as the sharp drop in profitability raises concerns despite stable revenues. The primary catalyst to watch is the successful CDSCO inspection and subsequent commercialization of the Jadcherla facility.

Balaxi Pharma Q3 Revenue Recovers to ₹72.5 Cr; Jadcherla Plant Ready for CDSCO Inspection

🔵 WATCH ⭐ 7/10

EARNINGS 📅 28 Jan 2026, 02:47 PM

Balaxi Pharmaceuticals reported a consolidated revenue of ₹72.54 crore for Q3 FY26, representing a strong 29% sequential growth compared to Q2 FY26, though it remained flat year-on-year. Consolidated net profit saw a sharp decline to ₹30.50 lakhs from ₹5.36 crore in the previous year's corresponding quarter, primarily due to increased administrative and employee costs. A major operational milestone was achieved as the Jadcherla formulation plant reached full readiness for CDSCO inspection after successful test manufacturing. The company also announced the resignation of its Company Secretary, Mohith Kumar Khandelwal, effective January 29, 2026.

Consolidated Revenue from operations for Q3 FY26 stood at ₹72.54 crore, up from ₹56.18 crore in Q2 FY26.
Consolidated Net Profit fell significantly to ₹30.50 lakhs from ₹5.36 crore in Q3 FY25.
Jadcherla formulation facility is 100% ready for CDSCO inspection with successful test batches of Paracetamol and Piroxicam completed.
Administrative expenses increased to ₹7.50 crore in Q3 FY26 compared to ₹6.15 crore in Q3 FY25.
Nine-month consolidated revenue for FY26 reached ₹199.46 crore with a net profit of ₹80.41 lakhs.

💡 Investors should focus on the upcoming CDSCO inspection results for the Jadcherla plant, as commercialization of this facility is the key catalyst for future margin improvement. While sequential revenue growth is positive, the sharp year-on-year profit compression warrants a cautious approach until operational leverage from the new plant kicks in.

Balaxi Pharmaceuticals Submits SEBI Reg 74(5) Compliance Certificate for Q3 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 07 Jan 2026, 12:48 PM

Balaxi Pharmaceuticals has filed its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by its Registrar and Share Transfer Agent, Aarthi Consultants Private Limited, covers the period from October 1, 2025, to December 31, 2025. It confirms that the company has processed dematerialization requests and mutilated physical certificates within the mandated 15-day timeframe. This is a standard procedural filing required for all listed entities in India to ensure regulatory transparency.

Compliance certificate submitted for the quarter ended December 31, 2025.
Confirmation provided by Registrar and Share Transfer Agent, Aarthi Consultants Private Limited.
Dematerialization requests were processed and physical certificates cancelled within 15 days of receipt.
The name of the depository has been substituted as the registered owner in the company's records.

💡 No action is required as this is a routine administrative filing. Investors should continue to monitor the company's upcoming quarterly financial results for material performance updates.

View All BALAXI Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Consolidated revenue for Q2 FY26 was INR 56.17 Cr, representing a 27.4% YoY decline from INR 77.38 Cr. The pharmaceutical product mix is dominated by Tablets at 42%, followed by Capsules at 16%, Injectables at 15%, and Liquids at 11%. The group also generates revenue from construction materials and FMCG products in Angola, though specific segment growth percentages for these are not disclosed.

Geographic Revenue Split

As of Q2 FY26, Africa (primarily Angola) accounts for 63% of revenue, while Latin America (LATAM), including the Dominican Republic and Guatemala, contributes 37%.

Profitability Margins

Gross Margin improved to 48.3% in Q2 FY26, up 540 bps from 42.9% in Q2 FY25. However, PAT Margin collapsed to 0.4% in Q2 FY26 from 5.9% in Q2 FY25, a decline of 550 bps, driven by increased marketing spend and a shift toward institutional sales.

EBITDA Margin

EBITDA Margin for Q2 FY26 was 2.1%, a significant contraction of 1158 bps from 13.7% in Q2 FY25. EBITDA fell 88.9% YoY from INR 10.59 Cr to INR 1.17 Cr.

Capital Expenditure

The company has transitioned to an 'Asset Right' model by commissioning its first pharmaceutical formulation plant in Jadcherla, Hyderabad. Additionally, the board approved an equity infusion of up to USD 4 million (approx. INR 33.5 Cr) into its Dubai subsidiary, Balaxi Global FZCO, for operational expansion.

Credit Rating & Borrowing

CRISIL revised the outlook to 'Negative' from 'Stable' on November 13, 2025, while reaffirming the long-term rating at 'CRISIL BBB+'. The revision is due to profitability pressure and an elongated working capital cycle. Gearing was healthy at 0.25 times as of March 31, 2025.

⚙️ Operational Drivers

Raw Materials

The company primarily procures finished pharmaceutical formulations (white-labeled) for its distribution business. With the new Jadcherla plant, raw materials will include Active Pharmaceutical Ingredients (APIs) for tablets, capsules, and injectables, though specific chemical names and cost percentages are not disclosed.

Import Sources

Historically sourced from various third-party manufacturers; the new manufacturing unit is located in a Pharma SEZ in Jadcherla, Hyderabad, India.

Key Suppliers

Not specifically named in the documents, but the company utilizes a network of third-party manufacturers for its branded and generic products.

Capacity Expansion

The company recently completed and commissioned its first pharmaceutical manufacturing facility in Jadcherla, Hyderabad, to integrate manufacturing with its existing distribution network.

Raw Material Costs

Gross profit of INR 27.14 Cr on revenue of INR 56.17 Cr implies direct material/procurement costs are approximately 51.7% of revenue as of Q2 FY26.

Manufacturing Efficiency

The Jadcherla plant is expected to drive operational integration and margin improvement, though specific utilization rates for the new facility are not yet reported.

Logistics & Distribution

The company operates as a conglomerate spanning four continents with a focus on front-end distribution in specialized markets like Angola and LATAM.

📈 Strategic Growth

Expected Growth Rate

10%

Growth Strategy

Growth is targeted through the 'Asset Right' model, utilizing the new Jadcherla manufacturing facility to capture higher margins. The company is also expanding its footprint in LATAM (Honduras, El Salvador) and shifting its business mix toward institutional sales to increase volume, supported by a USD 4 million investment in its Dubai distribution hub.

Products & Services

Pharmaceutical formulations including Antibiotics (41% of therapeutic mix), Analgesics (15%), and other medicines in Tablet, Capsule, and Injectable forms. Also sells construction materials and FMCG products in specific markets.

Brand Portfolio

Balaxi

New Products/Services

Expansion of the product portfolio through the new Jadcherla plant, focusing on branded generics (40% of current mix) and pure generics (60%).

Market Expansion

Targeting deeper penetration in LATAM markets including the Dominican Republic, Guatemala, Honduras, and El Salvador.

Market Share & Ranking

Established market position in Angola, Dominican Republic, and Guatemala; specific percentage ranking not disclosed.

Strategic Alliances

The group operates through various wholly-owned subsidiaries like Balaxi Global FZCO (Dubai) and local entities in Guatemala, Dominica, Honduras, and Central Africa.

🌍 External Factors

Industry Trends

The industry is seeing a shift toward local manufacturing and institutional procurement. Balaxi is positioning itself by moving from a pure distribution model to an integrated manufacturing-and-distribution ('Asset Right') model.

Competitive Landscape

Competes with other generic pharmaceutical exporters and local distributors in specialized emerging markets.

Competitive Moat

Moat is built on deep distribution expertise in difficult-to-penetrate markets and a 12-24 month regulatory lead time for product registrations, which creates a barrier to entry for competitors.

Macro Economic Sensitivity

Highly sensitive to the economic stability of Angola and Latin American countries. GDP fluctuations in these regions directly impact healthcare spending and construction demand.

Consumer Behavior

Demand is driven by essential healthcare needs (Antibiotics/Analgesics) and infrastructure development (construction materials) in emerging economies.

Geopolitical Risks

Vulnerable to economic uncertainties and regulatory changes in African and LATAM regions.

⚖️ Regulatory & Governance

Industry Regulations

Operations are subject to stringent local pharmaceutical registration processes (12-24 months) and compliance with local regulatory frameworks in each country of operation.

Taxation Policy Impact

The new manufacturing unit is located in a Pharma SEZ, which typically offers fiscal benefits; consolidated tax provision was INR 1.93 Cr for the reported period in the MDA.

Legal Contingencies

The company reported compliance with the Sexual Harassment of Women at Workplace Act with zero complaints received during the year. No major pending court cases with values were disclosed in the provided excerpts.

⚠️ Risk Analysis

Key Uncertainties

Currency volatility in Angola and the success of the transition to institutional sales are the primary uncertainties, with potential to impact net cash accruals if they fall below INR 20 Cr.